Sunnyvale, CA, May 16, 2018 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, announces that the company scored 100% on clinical laboratory proficiency testing conducted by the College of American Pathologists (CAP). Arrayit received a perfect score in highly quantitative measurements of immunoglobulin E (IgE), the antibodies in the human bloodstream indicative of allergy and asthma. The CAP SA2018 Diagnostic Immunology Survey proficiency test included 1,677 clinical laboratories utilizing IgE testing equipment manufactured by major corporations in the life sciences, molecular diagnostics and pharmaceutical markets. CAP, the international proficiency testing leader, ensures and improves healthcare quality by fostering clinical excellence through the impartial and carefully-supervised proficiency testing process.
Arrayit uses its patented and proprietary microarray technology to accurately and rapidly test IgE levels in patient blood card specimens shipped to its Silicon Valley clinical laboratory by hospitals, health maintenance organizations (HMOs), clinical laboratories, insured patients in physician groups, and consumers through the assistance of a medical doctor. Arrayit leverages miniaturization, allergen and sample multiplexing, and a high degree of robotic and software automation to deliver test results quickly and non-invasively using finger stick blood sampling.
Arrayit CEO Rene Schena states, “This independent, third party validation, as required under the Clinical Laboratory Improvement Amendments (CLIA), proves the accuracy and precision of our innovative microarray platform in an unbiased study protocol involving blinded specimens and rigorous oversight by the industry-leading College of American Pathologists. This achievement punctuates Arrayit’s commitment to superior quality standards as we provide personalized medical information to doctors to improve patient health and wellness.”
Arrayit Corporation, headquartered in Sunnyvale, California, leads and empowers the research, biotechnology, pharmaceutical, clinical and healthcare sectors through the discovery, development and manufacture of proprietary life science and personalized medicine products and services to advance biomedical research and improve wellness and human health. Please visit www.arrayit.com for more information.
Safe Harbor Statement
We have identified forward-looking statements by using words such as "expect", "believe", and "should". Although we believe our expectations are reasonable, our operations involve a number of risks and uncertainties that are beyond our control, and these statements may turn out not to be true. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's public filings.